Antiretroviral Agent |
Overall Effect or Recommendation |
NRTIs |
No effect |
NNRTIs |
|
|
Progestin levels markedly decreased Effectiveness of emergency contraception may be diminished Barrier method should be used in addition to this method |
|
No dose adjustment needed No additional contraceptive protection needed |
|
No dose adjustment needed No additional contraceptive protection needed |
|
No dose adjustment needed No additional contraceptive protection needed |
|
No dose adjustment needed No additional contraceptive protection needed |
PIs |
|
|
COC should contain no more than 30 µg of ethinyl estradiol No additional contraceptive protection needed |
|
Decreases in ethinyl estradiol and marked increases in [drug: drospirenone] progestin Contraindicated with [drug: drospirenone]-containing hormonal contraceptive due to potential for hyperkalemia Consider alternative or additional contraceptive method |
|
[drug: Ritonavir] inhibits CYP3A4, which may increase contraceptive hormone levels No additional contraceptive protection needed |
|
Decreases in ethinyl estradiol and marked increases in [drug: drospirenone] progestin Clinical monitoring recommended with [drug: drospirenone]-containing hormonal contraceptive due to potential for hyperkalemia Consider alternative or additional contraceptive method |
|
Small decrease in progestin levels Additional or alternative method recommended |
|
Decreases in ethinyl estradiol and progestin No additional contraceptive protection needed |
Integrase Inhibitors |
|
|
No additional contraceptive protection needed |
|
Ethinyl estradiol levels decreased Progestin levels increased No additional contraceptive protection needed |
|
No additional contraceptive protection needed |
|
No additional contraceptive protection needed |
CCR5 Antagonist |
|
|
No additional contraceptive protection needed |